

03CO
11



Attorney Docket No. 22918/1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Lucia Irene Gonzalez-Villasenor
Application No.: 10/080,919 Group Art Unit:
FILED: February 22, 2002 Examiner:
FOR: Methods and Composition for Production of Recombinant Peptides

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner of Patents, Washington, D.C. 20231 on:

By:

Michelle A. Phinney

Date

**INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE THE
MAILING DATE OF A FIRST OFFICE ACTION ON THE MERITS)**

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant hereby submits an Information Disclosure Statement for consideration by the Examiner.

Application No.: 10/080,919

Filed: February 22, 2002

Group Art Unit:

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- a. X **Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.**

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

- a. X Except as may be indicated below in (b), **all of the patents, publications or other information are in the English language** or were cited in an English language Search Report, a copy of which is attached hereto **(concise explanation not required).**
- b. A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:
- c. The following additional information is provided for the Examiner's consideration:

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)
(check one box)

- a. _____ within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.
- b. _____ within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.
- c. X before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or, if no certification has been made, charge our deposit account a fee in the amount of \$240.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

- a. _____ No certification; therefore, a fee in the amount of \$240.00 is required by 37 C.F.R. . § 1.17(p).
- or
- b. X See the certification below. No fee is required.

Application No.: 10/080,919
Filed: February 22, 2002
Group Art Unit:

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby certifies that

- a. _____ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- b. _____ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.
- c. _____ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

_____ Please charge Deposit Account No. 500369 in the amount of \$180.00 for the above-indicated fee. A triplicate copy of this paper is attached.

 X No fee is required.

Application No.: 10/080,919
Filed: February 22, 2002
Group Art Unit:

VII. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.704(d) (PATENT TERM
ADJUSTMENT)

Applies to original applications (other than design) filed on or after May 29, 2000


- a. _____ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- b. X Enclosed herewith is form PTO-1449.
- c. X Copies of cited references are enclosed.
- d. _____ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 500369.


Respectfully submitted,

Date: 2


Thomas M. Saunders, Esq.
Registration No. 29,585
Customer No. 21710
Brown Rudnick Berlack Israels LLP
One Financial Center
Boston, MA 02111
Tel: (617) 856-8284
Fax: (617) 856-8201




FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY DOCKET NO. 22918/1		SERIAL NO. 10/080,919	
				APPLICANT(S): Lucia Irene Gonzalez-Villasenor			
				FILING DATE: February 22, 2002		ART UNIT:	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR
		5,523,215	06/04/1996	Cousens et. al.	435	69.1	
		4,677, 196	06/30/1987	Rausch et. al.	530	412	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
		EP 0 433 225 B1	Nov. 27 1990	EPO	C07K	14/495	Y
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
1	"Recombinant-DNA-derived bovine growth hormone from <i>Escherichia coli</i> ", Keith E. Langley et. al., <u>Eur J. Biochem.</u> 163, pp 313-321, (1987)						
2	"Plasminogen activator inhibitor-1 fused with erythropoietin (EPO) mimetic peptide (EMP) enhances the EPO activity of EMP", Le-tian Kuai et.al., <u>J. Peptide Res.</u> , 56, 2000, pp 59-62						
3	"Biopharmaceutical formulation", J. Ching Lee, <u>Current Opinion in Biotechnology</u> , 2000, 11, pp 81-84						
4	"Purification and Characterization of Human Interleukin-1 Expressed in <i>Escherichia Coli</i> ", Shirley R. Kronheim et.al., <u>Bio Technology</u> , Vol. 4, December 1986, pp 1078-1082						
5	"Expression, renaturation and purification of recombinant human interleukin 4 from <i>Escherichia coli</i> ", Anita van Kimmenade et. al., <u>Eur. J. Biochem.</u> pp 109-114 (1988)						
6	"Expression of a biologically active fragment of human IgE ε chain in <i>Escherichia coli</i> , Fu-Tong Liu et. al., <u>Proc. Natl. Acad. Sci. USA</u> . Vol. 81, pp 5369-5373. September 1984						
7	"Renaturation of <i>Escherichia coli</i> Tryptophanase after Exposure to 8 M Urea, Evidence for the Existence of Nucleation Centers", Jacqueline London et. al., <u>Eur. J. Biochem.</u> 47, 409-415 (1974)						
8	"Inclusion Bodies from Proteins Produced at High Levels in <i>Escherichia coli</i> ", Joanna K. Krueger et. al., <u>Amer. Assoc. for the Adv. Science</u> , 1990, pp 136-142						
9	"Refolding of Recombinant Proteins", Tadahiko Kohno et. al., <u>Methods in Enzymology</u> , Vol 185, pp 187-195, 1990						
10	" <i>E. coli</i> expression and characterization of a mutant troponin I with the three cysteine residues substituted", Lan Kluwe et. al., <u>FEBS</u> , Vol 323, number 1.2, pp 83-88, May 1993						
Examiner:					Date:		




FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY DOCKET NO. 22918/1		SERIAL NO. 10/080,919	
				APPLICANT(S): Lucia Irene Gonzalez-Villasenor			
				FILING DATE: February 22, 2002		ART UNIT:	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
11	"Production of a biologically active novel goldfish growth hormone in <i>Escherichia coli</i> , Soheil S. Mahmoud et. al., <u>Comparative Biochemistry and Physiology</u> , Part B, Vol 120, 1998, pp 657-663						
11 A	"Intermediates in the Folding Reactions of Small Proteins", Peter S. Kim et. al., <u>Annu. Rev. Biochem.</u> , 1990, 59, 631-660						
12	"Refolding and Association of Oligomeric Proteins", Rainer Jaenicke et. al., <u>Methods in Enzymology</u> , 1986, 131, pp 218-250						
13	"Preparation of Biologically Active Platelet-Derived Growth Type BB from a Fusion Protein Expressed in <i>Escherichia coli</i> ", J. Hoppe et. al., <u>Biochemistry</u> , 1989, 28, 2956-2960						
14	"Pathways of Protein Folding". C. Robert Matthews, <u>Annu. Rev. Biochem.</u> 1993, 62, 653-683						
15	"The Purification of eukaryotic polypeptides synthesized in <i>Escherichia coli</i> ", Fiona A. O. Marston, <u>Biochem. J.</u> (1986), 240, 1-12						
16	"Purification of biologically active simian virus 40 small tumor antigen", Ilan Bikel et. al., <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 80, pp 906-910, February 1983						
17	"Recombinant Chicken and Bovine Growth Hormones Accelerate Growth in Aquacultured Juvenile Pacific Salmon <i>Oncorhynchus Kisutch</i> ", Jacqueline, A. Gill et. al, <u>Bio/Technology</u> , Vol 3, July 1985, pp 643-646						
18	"Renaturation of Enzymes after Polyacrylamide Gel Electrophoresis in the Presence of Sodium Dodecyl Sulfate", Sanford A. Lacks et. al., <u>The Journal of Biological Chemistry</u> , Vol. 255, No. 15, August 10 1980, pp 7467-7473						
19	"Cloning and expression of cDNA for salmon growth hormone in <i>Escherichia coli</i> ", Susumu Sekine et. al., <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 82, July 1985, pp 4306-4310						
20	"Purification of Calf Prochymosin (Prorennin) Synthesized in <i>Escherichia Coli</i> , Fiona A.O. Marston et. al., <u>Bio/Technology</u> , September 1984, pp 800-804						
Examiner:					Date:		




FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY DOCKET NO. 22918/1		SERIAL NO. 10/080,919	
				APPLICANT(S): Lucia Irene Gonzalez-Villasenor			
				FILING DATE: February 22, 2002		ART UNIT:	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
21	"Expression and equilibrium denaturation of cardiac troponin I: stabilization of a folding intermediate during denaturation by urea", Nihmat Morjana et al., <u>Biotechnol. Appl. Biochem.</u> (1998), 28, pp 7-17						
22	"The Cyanogen Bromide Reaction", Erhard Gross, <u>Cleavage of Peptide Chains</u> , pp 238-263						
23	"Gel Electrophoresis and Isoelectric Focusing of Proteins - Selected Techniques", R.C. Allen et. al., 1984						
24	"In vitro folding of inclusion body proteins", Rainer Rudolph et. al., <u>The FASEB Journal</u> , January 1996, Vol 10, pp 49-56						
25	"Purification and Immunogenicity of Fusion VP1 Protein of Foot and Mouth Disease Virus", Steven J. Shire et. al., <u>Biochemistry</u> , 1984, 23, 6474-6480						
26	"Examination of calf prochymosin accumulation in <i>Escherichia coli</i> : disulphide linkages are a structural component of prochymosin-containing inclusion bodies", J.M. Schoemaker et. al., <u>The EMBO Journal</u> , 1985, Vol. 4, No. 3, pp 775-780						
27	"Recovery of soluble human renin from inclusion bodies produced in recombinant <i>Escherichia coli</i> ", Satish K. Sharma, <u>Journal of Biotechnology</u> , 4 (1986) 119-124						
28	"Isolation and purification of protein granules from <i>Escherichia coli</i> cells overproducing bovine growth hormone", Ronald G. Schoner et. al., <u>Bio Technology</u> , February 1985, pp 151-154						
29	"Size and density of protein inclusion bodies", G. Taylor et. al., <u>Bio/Technology</u> , Vol 4, June 1986, pp 553-557						
30	"Alteration of catalytic properties of chymosin by site-directed mutagenesis", Junko Suzuki et. al., <u>Protein Engineering</u> , Vol. 2, No. 7, pp 563-569, 1989						
31	"Site-directed mutagenesis reveals functional contribution of Thr218, Lys220 and Asp304 in chymosin", Junko Suzuki et. al., <u>Protein Engineering</u> , Vol. 4, No. 1, pp 69-71, 1990						
Examiner:					Date:		



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY DOCKET NO. 22918/1		SERIAL NO. 10/080,919	
				APPLICANT(S): Lucia Irene Gonzalez-Villasenor			
				FILING DATE: February 22, 2002		ART UNIT:	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
32		"Purification of recombinant salmon growth hormone expressed in <i>Escherichia coli</i> , Seiji Sugimoto, <u>Biotechnology Letters</u> , Vol. 13, No. 6, 389-394, (1991)					
33		"Protein engineering to optimize recombinant protein purification", Mathias Uhlen et. al., <u>Biochemical Society Transactions</u> , Vol 16, pp 111-115, 1988					
34		"Solubilization and activation of recombinant calf prochymosin from <i>Escherichia coli</i> ", FIONA A. O. MARSTON, et al., <u>613th Meeting, Cardiff</u> , Vol. 13, pg. 1035					
35		"Sequencing of a cDNA encoding the human fast-twitch skeletal muscle isoform of troponin I", Lei Zhu et. al. <u>Biochimica et Biophysica Acta</u> 1217 (1994) 338-340					
36		"Reconstitution of Lactic Dehydrogenase. Noncovalent Aggregation vs. Reactivation. 1. Physical Properties and Kinetics of Aggregation". Gerd Zettlmeissl et. al., <u>Physical Properties of LDH Aggregates</u> , Vol 18, No. 25, 1979, 5567-5571					
37		"Increase of Solubility of Foreign Proteins in <i>Escherichia coli</i> by Coproduction of the Bacterial Thioredoxin". Takashi Yasukawa; <u>The Journal of Biological Chemistry</u> , Vol. 270, No. 43, October 27, 1995, pp 25328-25331					
38		"Efficient and Rapid Affinity Purification of Proteins Using Recombinant Fusion Proteases", Philip A. Walker et. al., <u>Bio/Technology</u> , Vol. 12, June 1994, pp 601-605					
39		"Effects of Low Concentrations of Guanidine. HCl on the Reconstitution of Lactic Dehydrogenase from Pig Muscle <i>in vitro</i> - Evidence for Guanidine Binding to the Native Enzyme", Gerd Zettlmeissl et. al., <u>Eur. J.Biochem</u> , 100, pp 593-598 (1979)					
40		"High-level direct expression of semi-synthetic human interleukin-6 in <i>Escherichia coli</i> and production of n-terminus met-free product", Hisahi Yasueda et. al., <u>Bio-Technology</u> , Vol. 8, November 1990, pp 1036-1040					
Examiner:					Date:		



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY DOCKET NO. 22918/1		SERIAL NO. 10/080,919	
				APPLICANT(S): Lucia Irene Gonzalez-Villasenor			
				FILING DATE: February 22, 2002		ART UNIT:	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
41	"Troponin I is present in human cartilage and inhibits angiogenesis", Marsha A. Moses et. al., <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 96, pp 2645-2650, March 1999						
42	"Structure, evolution, and regulation of a fast skeletal muscle troponin I gene", Albert S. Baldwin et. al., <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 82, pp 8080-8084, December 1985						
43	"Utilization of Zeolite Y in the removal of anionic, cationic and nonionic detergents during purification of proteins", Zoltan Blum et. al., <u>Biotechnology Techniques</u> , Vol 5, No. 1, pp 49-54, (1991)						
44	"Principles that govern the folding of Protein Chains", Christian B. Anfinsen, <u>SCIENCE</u> , 20 July 1973, Volume 181, Number 4096, pp 223-230						
45	"Overexpression of human cardiac troponin-I and troponin-C in <i>Escherichia coli</i> and their purification and characterization - Two point mutations allow high-level expression of troponin-I", Eman AL-HILLAWI et. al., <u>Eur. J. Biochem.</u> , 225, pp 1195-1201, (1994)						
46	"Recombinant protein expression in <i>Escherichia coli</i> ", Francois Baneyx, <u>Current Opinion in Biotechnology</u> , 1999, Vol. 10, pp 411-421						
47	"Structure and morphology of protein inclusion bodies in <i>Escherichia coli</i> ", Gregory A. Bowden, <u>Bio/Technology</u> , Vol 9, August 1991, pp 725-730						
48	"Renaturation, purification and characterization of recombinant F _{ab} -fragments produced in <i>Escherichia coli</i> ", Johannes Buchner et. al., <u>Bio/Technology</u> , Vol. 9, February 1991, pp 157-162						
49	"Stabilization of Protein Structure by Sugars", Tsutomu Arakawa et. al., <u>Biochemistry</u> , 1982, Vol. 21, pp 6536-6544						
50	"Synthesis and cloning of a gene coding for a fusion protein containing mouse epidermal growth factor", G. Allen et.al., <u>Journal of Biotechnology</u> , Vol. 5, (1987) pp 93-114						
51	"Denatured States of Proteins", Ken A. Dill, <u>Annu. Rev. Biochem.</u> , 1991, Vol. 60, pp 795-825						
Examiner:					Date:		




FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY DOCKET NO. 22918/1		SERIAL NO. 10/080,919	
				APPLICANT(S): Lucia Irene Gonzalez-Villasenor			
				FILING DATE: February 22, 2002		ART UNIT:	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
52	"Choice of Cellular Protein Expression System", David Gray et. al., <u>Current Protocols in Protein Science</u> , (2000), pp 5.16.1-5.16.34						
53	"Chromatofocusing", Alan Williams, <u>Current Protocols in Protein Science</u> , (1997), pp 8.5.1-8.5.10						
54	"Overview of Protein Purification and Characterization", R.K. Scopes, <u>Current Protocols in Protein Science</u> , (1995), pp 1.1.1-1.1.5						
55	"Strategies for Protein Purification", R.K. Scopes, <u>Current Protocols in Protein Science</u> , (1995), pp 1.2.1-1.3.7						
56	"Conventional Chromatographic Separations", Ben. M. Dunn, <u>Current Protocols in Protein Science</u> , (1997), pp 8.0.1-8.1.9						
57	"Dominant Forces in Protein Folding", Ken A. Dill, <u>Biochemistry</u> , Vol. 29, Number 31, August 7, 1990, pp 7133-7155						
58	"Nativelike Secondary Structure in Interleukin-1B Inclusion Bodies by Attenuated Total Reflectance FTIR", Keith Oberg et. al., <u>Biochemistry</u> , 1994, Vol. 33, pp 2628-2634						
59	"Efficient renaturation and fibrinolytic properties of prourokinase and a deletion mutant expressed in <i>Escherichia coli</i> as inclusion bodies", Gaetano Orsini et. al., <u>Eur. J. Biochem</u> , Vol. 195, pp 691-697 (1991)						
60	"Culture of Yeast for the Production of Heterologous Proteins", Michael A. Romanos et. al., <u>Current Protocols in Protein Science</u> , (1995), pp 5.8.1-5.8.17						
61	"Solubility as a function of protein structure and solvent components", Catherine H. Schein, <u>Bio/Technology</u> , Vol. 8, April 1990, pp 308-317						
Examiner:					Date:		




Sheet 7 of 10

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				DOCKET NO. 22918/1		SERIAL NO. 10/080,919	
				APPLICANT(S): Lucia Irene Gonzalez-Villasenor			
				FILING DATE: February 22, 2002		ART UNIT:	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
62	"Synthesis of calf prochymosin (prorennin) in <i>Escherichia coli</i> ", J.S. Emtage, <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 80, pp 3671-3675, June 1983						
63	"High-Level Expression in <i>Escherichia coli</i> of Biologically Active Bovine Growth Hormone", Henry J. George et. al., <u>DNA</u> , Volume 4, Number 4, 1985, pp 273-281						
64	"Purification of Recombinant Proteins", Paul T. Wingfield, <u>Current Protocols in Protein Science</u> , 1997, 6.0.1.-6.7.10						
65	"Reconstitution of Lactic Dehydrogenase. Noncovalent Aggregation vs. Reactivation. 2. Reactivation of Irreversibly Denatured Aggregates", Rainer Rudolph et. al., <u>Biochemistry</u> , Vol 18, No. 25, 1979, pp 5572-5575						
66	"Gene Expression in Recombinant <i>Escherichia coli</i> ", Joan Stader, 1995, pp 1-51						
67	"Gene Expression in Recombinant Bacillus", Matti Sarvas, <u>Gene Expression in Recombinant Microorganisms</u> , 1995, pp 55-120						
68	"Use of Stabilizing Additives", Ciaran O'Fagain, <u>Stabilizing Protein Function</u> , 1997, pp 69-79						
69	"Recombinant human insulin-like growth factor II expressed in <i>Escherichia coli</i> ", Thomas C. Furman et. al., <u>BioTechnology</u> , Vol. 5, October 1987, pp 1047-1051						
70	"High-Level Expression and Purification of the Recombinant Diphtheria Fusion Toxin DTGM for PHASE I Clinical Trials", Arthur E. Frankel et. al., <u>Protein Expression and Purification</u> , 16, 190-201, (1999)						
Examiner:					Date:		



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY DOCKET NO. 22918/1		SERIAL NO. 10/080,919	
				APPLICANT(S): Lucia Irene Gonzalez-Villasenor			
				FILING DATE: February 22, 2002		ART UNIT:	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
7	"Recovery of soluble, biologically active recombinant proteins from total bacterial lysates using ion exchange resin", Adolf Hoess et. al., <u>Bio/Technology</u> , Vol. 6, October 1998, pp 1214-1217						
72	"Renaturation of Recombinant Proteins Produced as Inclusion Bodies", Bernhard E. Fischer, <u>Biotech. Adv.</u> , Vol. 12, pp 89-101, 1994						
73	"Refolding and crystallographic studies of eukaryotic proteins produced in <i>Escherichia coli</i> ", Kiyoshi Nagai et. al., <u>Biochemical Society Transactions</u> , 1988, Vol. 16, pp 108-110						
74	"Protein folding intermediates and inclusion body formation", Anna Mittraki et. al., <u>Bio/Technology</u> , Vol. 7, July 1989, pp 690-697						
75	"Overview of Protein Expression in <i>Saccharomyces cerevisiae</i> ", Robert L. Strausberg, <u>Production of Recombinant Proteins</u> , 1995, pp 5.6.1-5.6.7						
76	"Production of recombinant proteins", Paul T. Wingfield, <u>Current Protocols in Protein Science</u> , Supplement 20, 2000, pp 5.0.1-5.16.25						
77	"Fermentation and Growth of <i>Escherichia coli</i> for Optimal Protein Production", Alain Bernard et. al., <u>Current Protocols in Protein Science</u> , 1995, pp 5.3.1-5.3.18						
78	"Protein Folding and its Implications for the Production of Recombinant Proteins", Roman Hlodan et. al., <u>Biotechnology and Genetic Engineering Reviews</u> , Vol. 9, December 1991, pp 47-88						
79	"Reconstitution of Rabbit Skeletal Muscle Troponin from the Recombinant Subunits All Exressed in and Purified from <i>E. coli</i> ", Setsuko Fujita-Becker et. al., <u>J. Biochem.</u> , 114, 438-444, (1993)						
80	"A novel sequential procedure to enhance the renaturation of recombinant protein from <i>Escherichia coli</i> inclusion bodies", Bernhard Fischer et. al., <u>Protein Engineering</u> , Vol. 5, No. 6, pp 593-596, 1992						
Examiner:					Date:		



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				PATENT & TRADEMARK OFFICE DOCKET NO. 22918/1		SERIAL NO. 10/080,919	
				APPLICANT(S): Lucia Irene Gonzalez-Villasenor			
				FILING DATE: February 22, 2002		ART UNIT:	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
81	"Optimized procedures for purification and solubilization of basic fibroblast growth factor inclusion bodies", D. Estape et. al., <u>Biotechnology Techniques</u> , Vol. 10, No. 7, July 1996, p 481-484						
82	"The Use of Zeolite Y in the Purification of Intra Cellular Accumulated Proteins from Genetically Engineered Cells, Hakan Eriksson et. al., <u>Biotechnology Techniques</u> , 1992, pp 239-244						
83	"Convenient and Efficient <i>In Vitro</i> Folding of Disulfide-Containing Globular Protein from Crude Bacterial Inclusion Bodies", Junichiro Futami et. al., <u>J. Biochem.</u> , Vol. 127, pp 435-444 (2000)						
84	"Enzyme Applications", M.D. Trevan et. al., <u>Biotechnology: The Biological Principles</u> , 1987, pp 203-210						
85	"Comparing the Refolding and Reoxidation of Recombinant Porcine Growth Hormone from a Urea Denatured State and from <i>Escheria coli</i> Inclusion Bodies", Michael Cardamone et. al., <u>Biochemistry</u> 1995, Vol. 34, pp 5773-5794						
86	"The use of EDTA or Polymyxin with Lysozyme for the Recovery of Intracellular Products from <i>Escherichia coli</i> ", C.R. Dean et. al., <u>Biotechnology Techniques</u> , Volume 6, No. 2 March/April 1992 pp 133-138						
87 *	"Serodiagnosis of Antibodies to the Human AIDS Retrovirus with a Bacterially Synthesized <i>ENV</i> Polypeptide", Cirilo D. Cabradilla, <u>Bio/Technology</u> , Vol. 4, February 1986, pp 128-133						
88	"Aggregation and Denaturation of Apomyoglobin in Aqueous Urea Solutions", Linda R. De Young et. al., <u>Biochemistry</u> , 1993, 32, 3877-3886						
89	"Refolding of recombinant proteins", Eliana De Bernadez Clark, <u>Biochemical Engineering</u> , 1998, 9, 157-163						
90	"Pharmacoeconomics", Joseph F. Heyse et. al., <u>Encyclopedia of Biopharmaceutical Statistics</u> , 2000, pp 387-401						
91	"Recombinant DNA Proteins and Drug Discovery", Christopher Hentschel, <u>Genetically Engineered Human Therapeutic Drugs</u> , 1988, pp 3-6						
92	"Chapter 8. Bioproducts and Economics", Harvey W. Blanch et. al., <u>Biochemical Engineering</u> , 1996, pp 609-671						
Examiner:					Date:		



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY DOCKET NO. 22918/1		SERIAL NO. 10/080,919	
				APPLICANT(S): Lucia Irene Gonzalez-Villasenor			
				FILING DATE: February 22, 2002		ART UNIT:	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
93		"Solubilization of Protein Aggregates", Fiona A. O. Marston et. al., <u>Methods in Enzymology</u> , Vol. 182, pp 264-276, 1990					
94		"Development of an Intravenous γ -Globulin with Fc Activities", Y Masuho et. al, <u>Vox Sang.</u> 32: p 175-181 (1977)					
95		"Reversible protection of disulfide bonds followed by oxidative folding render recombinant hCGB highly immunogenic", Asok Mukhopadhyay, <u>Vaccine</u> , 18 (2000) 1802-1810					
96		"Refolding of Therapeutic Proteins Produced in <i>Escherichia coli</i> as Inclusion Bodies", Satoru Misawa et. al., <u>Biopolymers</u> , 51, 297-307, (1999)					
97		"Global Suppression of Protein Folding Defects and Inclusion Body Formation", Anna Mitraki et. al., <u>Science</u> , Vol. 253, pp 54-58					
98		"Structural characterization of the human fast skeletal muscle troponin I gene (TNN12)", Antony J. Mullen et. al., <u>GENE</u> , 242, (2000) 313-320					
Examiner:				Date:			